Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. (Nasdaq: PTCT) to acquire a portion of PTC\u2019s royalty interest in risdiplam for a one-time payment of $650 million.<\/p>\n\n\n\n
Risdiplam, to be marketed by Roche, is an investigational, orally administered survival motor neuron-2 (SMN2) splicing modifier for the treatment of spinal muscular atrophy (SMA). SMA is a severe, inherited, progressive neuromuscular disease that causes devastating muscle atrophy and disease-related complications. It is the most common genetic cause of infant mortality and one of the most common rare diseases, affecting approximately one in 11,000 babies.<\/p>\n\n\n\n
[\u2026]<\/p>\n\n\n\n
Wilmer Hale acted as legal advisor to PTC Therapeutics on the transaction. Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty Pharma.<\/p>\n\n\n\n
This text is a press release from Royalty Pharma. The full text version of the article can be found here: https:\/\/www.royaltypharma.com\/news-releases\/news-release-details\/royalty-pharma-acquires-royalty-interest-risdiplam-ptc<\/a><\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-23308","presseberichte","type-presseberichte","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/23308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte"}],"about":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/types\/presseberichte"}],"version-history":[{"count":0,"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/23308\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/media?parent=23308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}